CPMP recommends TKTX's Dynepo

The EMEA's Committee for Proprietary Medicinal Products recommended approval of Dynepo epoetin delta from Transkaryotic (TKTX) and partner Aventis (AVE)

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE